Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease
نویسندگان
چکیده
There is a pressing, global need for new therapies for neglected diseases such as Tuberculosis, Leishmaniasis and Chagas. Traditional lead discovery approaches, while effective have not been widely applied to neglected diseases as they are expensive and time consuming. At Institut Pasteur Korea, we have developed a core technology that enables the high content screening of hundreds of thousands of small molecules against the disease of interest. In doing so, we utilize relevant disease models that allow us to interrogate the disease in the context of the cell and the host-pathogen factors required for invasion, replication, persistence and release. The application of this core technology against Tuberculosis, Leishmaniasis and Chagas disease has resulted in the identification of novel, active compounds in less time and at less cost than traditional drug discovery methods. As these active compounds were identified in a cellular context, they can provide a more relevant starting point for new therapies.
منابع مشابه
Discovery of Novel Glucagon Receptor Antagonists Using Combined Pharmacophore Modeling and Docking
Glucagon and the glucagon receptor are most important molecules control over blood glucose concentrations. These two molecules are very important to studies of type 2 diabetic patients. In literature, several classes of small molecule antagonists of the human glucagon receptor have been reported. Glucagon receptor antagonist could decrease hepatic glucose output and improve glucose control in d...
متن کاملDiscovery of Novel Glucagon Receptor Antagonists Using Combined Pharmacophore Modeling and Docking
Glucagon and the glucagon receptor are most important molecules control over blood glucose concentrations. These two molecules are very important to studies of type 2 diabetic patients. In literature, several classes of small molecule antagonists of the human glucagon receptor have been reported. Glucagon receptor antagonist could decrease hepatic glucose output and improve glucose control in d...
متن کاملData Analysis Approaches in High Throughput Screening
With the advances in biotechnology, identification of new therapeutic targets, and better un‐ derstanding of human diseases, pharmaceutical companies and academic institutions have accelerated their efforts in drug discovery. The pipeline to obtain therapeutics often involves target identification and validation, lead discovery and optimization, pre-clinical animal studies, and eventually clini...
متن کاملA genome-wide RNAi screen identifies potential drug targets in a C. elegans model of α1-antitrypsin deficiency.
α1-Antitrypsin deficiency (ATD) is a common genetic disorder that can lead to end-stage liver and lung disease. Although liver transplantation remains the only therapy currently available, manipulation of the proteostasis network (PN) by small molecule therapeutics offers great promise. To accelerate the drug-discovery process for this disease, we first developed a semi-automated high-throughpu...
متن کامل